44108

(E)-3-Methylglutaconic acid

≥97.0% (HPLC)

Manufacturer: Supelco

CAS Number: 372-42-9

Synonym(S): (2E)-3-Methyl-2-pentenedioic acid

Select a Size

Pack Size SKU Availability Price
50 MG 44108-50-MG In Stock ₹ 15,003.45

44108 - 50 MG

₹ 15,003.45

In Stock

Quantity

1

Base Price: ₹ 15,003.45

GST (18%): ₹ 2,700.621

Total Price: ₹ 17,704.071

Quality Level

100

Assay

≥97.0% (HPLC)

mp

137-143 °C

application(s)

clinical testing

format

neat

storage temp.

2-8°C

InChI

1S/C6H8O4/c1-4(2-5(7)8)3-6(9)10/h2H,3H2,1H3,(H,7,8)(H,9,10)/b4-2+

InChI key

WKRBKYFIJPGYQC-DUXPYHPUSA-N

Other Options

Image Product Name Manufacturer Price Range
(2E)-3-methylpent-2-enedioic acid
-- ₹ 28,925.00 - ₹ 1,17,658.00
(E)-3-Methylpentenedioic acid
-- ₹ 11,837.00 - ₹ 2,71,183.00
372-42-9 | (2E)-3-methylpent-2-enedioic acid
-- ₹ 37,914.00 - ₹ 1,47,028.00

Related Products

Img

Supelco

43987

analytical standard...

Img

Supelco

41467

analytical standard...

Img

Supelco

42183

analytical standard...

Img

Supelco

43534

analytical standard...

Img

Supelco

44041

analytical standard...

Description

  • Biochem/physiol Actions: 3-Methylglutaconic aciduria (MGCA) is a group of metabolic disorders characterized by increased urinary excretion of 3-methylglutaconic acid and 3-methylglutaric acid. Five distinct forms of MGCA have been recognized. MGCA type 1 is caused by primary deficiency of the mitochondrial enzyme 3-methylglutaconyl-CoA hydratase (3-MGCH), resulting in a block of leucine degradation. In all other types, the activities of 3-MGCH and other enzymes of leucine degradation are normal and the MGCA is thought to be secondary to a defect in another pathway. MGCA type 2, also known as Barth syndrome, is an X-linked cardiomyopathy associated with skeletal myopathy, neutropenia, and growth retardation. MGCA type 3, also referred to as Costeff optic atrophy syndrome, is an autosomal recessive disorder caused by mutations in the gene OPA3. It is characterized by early-onset bilateral optic atrophy, later-onset extrapyramidal dysfunction. MGCA type 5 caused by mutation in the DNAJC19 gene, is characterized by early-onset dilated cardiomyopathy with conduction defects, nonprogressive cerebellar ataxia, testicular dysgenesis, and growth failure. MGCA type 4 is the unclassified type, which includes all other patients with MGCA.

SAFETY INFORMATION

Pictograms

GHS07

Signal Word

Warning

Hazard Statements

H315,H319

Precautionary Statements

P264 - P280 - P302 + P352 - P305 + P351 + P338 - P332 + P313 - P337 + P313

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable